PeopleReign
Website: https://peoplereign.io
Type of Company: Software & application
Company Status: Active
Business: PeopleReign is an enterprise software company that provides a virtual agent for IT and HR Helpdesk.
Outcome:
Co-investors: Moxxie Ventures
IRVINE, Calif., and BOULDER, Colo. May 13, 2024 (GLOBE NEWSWIRE) Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) and OnKure, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing OnKure’s pipeline candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), including its lead program OKI-219, which is currently in a Phase 1 clinical trial for the treatment of solid tumors. Upon completion of the transaction, the combined company is expected to operate under the name OnKure Therapeutics, Inc., and trade on the Nasdaq Global Market under the ticker symbol “OKUR”.
“Until two years ago, Kishen Mangat was always a founder or an executive. Now he helps other companies grow their businesses.”
See more of this CoBiz Spring 2024 article covering the careers of its previous leadership award winners, including Kishen Mangat, BV General Partner here.
It's the end of an era at Cisco Systems.
John Chapman, the well-regarded cable industry vet and DOCSIS pioneer, confirmed that he will be leaving Cisco amid a recent wave of layoffs that will impact about 5% of the company's workforce – or roughly 4,000 jobs.
Chapman currently serves as CTO, broadband, and a fellow at Cisco, covering areas such as PON, fixed wireless access (FWA) and mobile.
He joined the company more than 34 years ago and recalls being interviewed by Cisco founders Leonard Bosack and Sandy Lerner. He came aboard while Cisco was still a private startup with about 20 design engineers and 70 people across the whole company, he recalls.
Software testing is hard. Even with the right talent in place, it doesn’t always go as planned — particularly when executed at scale. In a 2020 survey from Electric Cloud, 58% of developers blamed software bugs on test infrastructure and process issues — not design defects.
The market for software testing solutions is quite massive, unsurprisingly, with one estimate pegging it at $55.98 billion. There’s plenty of vendors in the space, from startups like Qase, EvaluAgent and Codegen to incumbents like Azure and AWS.
But a new entrant, Antithesis, thinks it can make a splash.
RADNOR, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (“CKD”) and other diseases driven by abnormally elevated aldosterone, today announced that it has entered into a securities purchase agreement with institutional accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $120 million, before deducting estimated fees and expenses.